TEXT +-

The MacTel Project

logo-mactelThe MacTel Project is an international research collaboration among clinicians and bench scientists to study idiopathic Macular Telangiectasia type 2, or MacTel. The MacTel Project aims to improve the clinical understanding of MacTel, raise awareness of the disease, and identify causes and appropriate treatments. It is a program of the Lowy Medical Research Institute, which sponsors the MacTel Project.

The disease was first described by Donald Gass in 1977. In the early 1990s, Donald Gass and Barbara Blodi described idiopathic Macular Telangiectasia type 2 in greater detail, and classified it as one of three distinct forms of idiopathic juxtafoveolar retinal telangiectasis. Little new information was published about MacTel following Gass and Blodi’s characterization. More than ten years later, that changed when a small group of clinicians and researchers convened to discuss MacTel. The MacTel Project was initiated in 2005 as a consequence of that meeting.

The MacTel project includes a natural history observation study, a registry of patients with MacTel, collaborative genetics and laboratory research programs, and an eye donor program. More than 30 centers around the world participate in the MacTel Project, making the search for information a truly global effort. These actions have dramatically improved the understanding of MacTel. They have also given patients the opportunity to participate in the search for new information and effective therapies.

One notable accomplishment of the MacTel Project is a more accurate description of the disease. Macular Telangiectasia type 2 was initially described by the blood vessel changes (telangiectasia) that occur in the retina, the light sensing tissue in the back of the eye. It is now understood that MacTel is not primarily a blood vessel disease. The blood vessel abnormalities occur secondary to other changes in the eye. It is now believed that MacTel is a neuronal disease with vascular abnormalities. Another notable accomplishment of the MacTel Project has been increased awareness of the disease among clinicians and vision science researchers. This has occurred due to clinicians and scientists involved in the MacTel Project who promote MacTel among colleagues as an important subject for research.  Lastly, the MacTel Project has been critical to the success of our clinical trials, as recruitment for the clinical trials was greatly facilitated by registry.

 

 

United Kingdom

Moorfields Eye Hospital
London, United Kingdom
Cathy Egan, MD
011 44 20 7566 2262
catherine.egan@moorfields.nhs.uk

×
United States

California

Scripps Research Institute
La Jolla, CA USA
Martin Friedlander, MD, PhD
858-784-9138
friedlan@scripps.edu

Jules Stein Eye Institute, UCLA
Los Angeles, CA USA
Jean-Pierre Hubschman, MD
310-206-5004
hubschman@jsei.ucla.edu

Florida

Bascom Palmer Eye Institute, University of Miami
Miami, FL USA
Philip Rosenfeld, MD
305-326-6538
prosenfeld@med.miami.edu

Massachusetts

Massachusetts Eye and Ear Infirmary
Boston, MA USA
Joan Miller, MD
617-578-3257
joan.miller@meei.harvard.edu

Michigan

University of Michigan, Kellogg Eye Center
Ann Arbor, MI USA
Grant Comer, MD
734-763-5906
gcomer@umich.edu

New York

Manhattan Eye, Ear & Throat Hospital
New York, NY USA
Michael Cooney, MD
212 861-9797
m.cooney@vrmny.com

The New York Eye and Ear Infirmary
New York, NY USA
Richard Rosen, MD
212-979-4284
rrosen@nyee.edu

Ohio

Retina Associates of Cleveland, Inc.
Cleveland, OH USA
Lawrence Singerman, MD
216-831-5700
lsingerman@retina-assoc.com

Pennsylvania

Scheie Eye Institute
Philadelphia, PA USA
Alexander Brucker, MD
215-662-8675
ajbrucke@mail.med.upenn.edu

Utah

University of Utah Medical Center
Salt Lake City, Utah
Paul Bernstein, MD, PhD.
801-581-6078
paul.bernstein@hsc.utah.edu

Virginia

The Retina Group of Washington
Fairfax, VA USA
Robert Murphy, MD
703-698-9335
rpmurphy@comcast.net

Wisconsin

University of Wisconsin
Madison, WI USA
Barbara Blodi, MD
608-263-6646
bablodi@wisc.edu

×
France

Hopital Lariboisiere
Paris, France
Alain Gaudric, MD
011 33 1 4995 2475
alain.gaudric@lrb.aphp.fr

×
Germany

Universitats-Augenklinik Bonn
Bonn, Germany
Frank Holz, MD
011 49 228 287 5647
Frank.Holz@ukb.uni-bonn.de

St. Franziskus Hospital
Muenster, Germany
Prof. Daniel Pauleikhoff
dapauleikhoff@muenster.de
Bjorn Padge, MD
011 49-251-93308-0
bjoern@padge.de

×
Israel

The Goldschleger Eye Institute
Tel Hashomer, Israel
Joseph Moisseiev, MD
011 972 3 5343462
Joseph.moisseiev@sheba.health.gov.il

×
Switzerland

Klinik und Poliklinik fur Augenheilkunde
Inselspita
University of Bern
Bern, Switzerland
Sebastian Wolf, MD, PhD
41 31 6328503
sebastian.wolf@insel.ch

×
Australia

Center for Eye Research Australia
Melbourne, Australia
Robyn Guymer, MD
011 61 3 9929 8393
rhg@unimelb.edu.au

Lions Eye Institute
Nedlands, Australia
Ian Constable, MD
011 61 8 9381 0882
ijc@cyllene.uwa.edu.au

Save Sight Institute
Sydney NSW Australia
Mark Gillies, MD, PhD
011 61 412 060 313
mark.gillies@sydney.edu.au

×